Publications :: GT Biopharma, Inc. (GTBP)

Engineering of Anti-CD133 Tri-Specific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC).

Schmohl JU, Felices M, Oh F, Lenvik AJ, Lebeau AM, Panyam J, Miller JS, Vallera DA.
Cancer Res Treat. 2017 Feb 20. doi: 10.4143/crt.2016.491. [Epub ahead of print]
PMID: 28231426

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.

Schmohl JU, Felices M, Todhunter D, Taras E, Miller JS, Vallera DA.
Oncotarget. 2016 Nov 8;7(45):73830-73844. doi: 10.18632/oncotarget.12073.
PMID: 27650544

Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.

Schmohl JU, Felices M, Taras E, Miller JS, Vallera DA.
Mol Ther. 2016 Aug;24(7):1312-22. doi: 10.1038/mt.2016.88. Epub 2016 May 9.
PMID: 27157665

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.

Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS.
Clin Cancer Res. 2016 Jul 15;22(14):3440-50. doi: 10.1158/1078-0432.CCR-15-2710. Epub 2016 Feb 4.
PMID: 26847056

Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.

Schmohl JU, Gleason MK, Dougherty PR, Miller JS, Vallera DA.
Target Oncol. 2016 Jun;11(3):353-61. doi: 10.1007/s11523-015-0391-8.
PMID: 26566946

Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.

Felices M, Lenvik TR, Davis ZB, Miller JS, Vallera DA.
Methods Mol Biol. 2016;1441:333-46. doi: 10.1007/978-1-4939-3684-7_28.
PMID: 27177679

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS.
Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20.
PMID: 24652987

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.

Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS.
Clin Cancer Res. 2013 Jul 15;19(14):3844-55. doi: 10.1158/1078-0432.CCR-13-0505. Epub 2013 May 20.
PMID: 23690482

Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR.
Cancer Biother Radiopharm. 2013 May;28(4):274-82. doi: 10.1089/cbr.2012.1329. Epub 2013 Apr 23.
PMID: 23611188

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS.
Mol Cancer Ther. 2012 Dec;11(12):2674-84. doi: 10.1158/1535-7163.MCT-12-0692. Epub 2012 Oct 17.
PMID: 23075808